Last update June 11, 2018
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Bilastine in other languages or writings:
Bilastine belongs to this group or family:
Main tradenames from several countries containing Bilastine in its composition:
|Protein Binding||84 - 90||%|
|VD||4.1 - 4.5||l/Kg|
|Tmax||0.9 - 1.4||hours|
|T½||10.9 - 14.5||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a second-generation antihistamine drug without sedative or antimuscarinic effects (AEMPS 2016, Wolthers 2013, Scaglione 2012, Conen 2011, Church 2011).
At latest update, relevant data on its excretion into breast milk were not found.
Due to a lack of sedative effect since it does not break through the blood-brain barrier (Scaglione 2012, Church 2011), and, a favorable pharmacokinetic profile (Togawa 2016, AEMPS 2016, Sádaba 2013), -high protein-binding capacity, and a medium oral bioavailability-, the risk for problems in the nursing infant is very low. However, until more and reliable data on this drug concerning breastfeeding is available, known safer options should be preferred, especially for breastfeeding mothers in the first month after birth or in case of prematurity.